Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa
Ferraris, M.
Minerva Medica 62(82): 3971-3973
1971
ISSN/ISBN: 0026-4806 PMID: 5125056 Document Number: 43353
Document emailed within 1 workday
Related Documents
Danielczyk, W.; Korten, J.J. 1971: Action of amantadine HCl alone and in combination with L-dopa on parkinsonism Medizinische Monatsschrift 25(10): 472-479Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Court, J.; Kase, J.C.; Palacios, E.; Mena, I. 1971: Treatment of parkinsonism with L-dopa Revista Medica de Chile 99(6): 399-401
Hernández Peniche, J.; Martínez Villar, C.; De León Charles, C. 1971: Treatment of parkinsonism with L-dopa Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 23(2): 125-132
Puca, F.M.; Bricolo, A.; Turella, G. 1972: Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes Revue Neurologique (Paris) 127(2): 313
Dzudza, M.; Dzudza, D. 1974: Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease Medicinski Arhiv 28(4): 407-415
Sweet, R.D.; McDowell, F.H. 1974: The "on-off" response to chronic L-DOPA treatment of Parkinsonism Advances in Neurology 5: 331-338
Sánchez Longo, L.P.; Cruz de León, C.; Rodríguez del Valle, J.; Hernández Ortiz, T. 1971: The history of the discovery of L-dopa as treatment in parkinsonism Boletin de la Asociacion Medica de Puerto Rico 63(2): 36-40
Ing, T.S.; Mahurkar, S.D.; Dunea, G.; Hayashi, J.A.; Klawans, H.L.; Markey, W.S. 1976: Removal of amantadine hydrochloride by dialysis in patients with renal insufficiency Canadian Medical Association Journal 115(6): 515
Garde, K.; Kruse-Larsen, C. 1971: Postmenopausal vaginal haemorrhage as a complication of treatment of Parkinsonism with L-dopa Ugeskrift for Laeger 133(18): 886-887
Nakamura, H.; Uyama, H.; Enomoto, H.; Kishima, Y.; Yamamoto, M.; Yoshida, K.; Okuda, Y.; Hirotani, T.; Kuroda, T.; Ito, H.; Matsuda, M.; Terabayashi, M.; Noguchi, S. 2003: The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C Hepato-Gastroenterology 50(49): 222-226
Megna, G.; Pennetta, R.; Andreula, C. 1977: Clinical and psychometric observations on the use of S-adenosylmethionine in parkinsonism during chronic L-dopa treatment Acta Neurologica 32(2): 204-217
Wajsbort, J.; Hemli, J.A.; Alfandary, I.; Yahel, M.; Siegfried, J. 1971: Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association Wiener Medizinische Wochenschrift 121(42): 741-745
Pakkenberg, H. 1973: Amantadine therapy in parkinsonism Ugeskrift for Laeger 135(3): 135-136
Andrews, C.J. 1972: Amantadine and L-dopa Australian and New Zealand Journal of Medicine 2(3): 292-293
Eisenlohr, J.J.; Gehlen, W. 1975: Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor) Der Nervenarzt 46(3): 128-135
Pennacchietti, M.; Aletto, P.M. 1971: On the action of amantadine in postencephalitic parkinsonism Minerva Medica 62(82): 3960-3962
Ambrosetto, C.; Martinelli, P. 1971: Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa Minerva Medica 62(82): 4017-4019
Ciuca, I.; Bulandra, R.; Serbanesco, L.; Ninosu, N. 1972: Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes Revue Neurologique (Paris) 127(2): 305-308
Flatberg, P. 1970: 1-dopa for parkinsonism Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 90(10): 1102-1103